Literature DB >> 20404009

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.

Tadashi Ishibashi1, Tomoko Horisawa, Kumiko Tokuda, Takeo Ishiyama, Masaaki Ogasa, Rie Tagashira, Kenji Matsumoto, Hiroyuki Nishikawa, Yoko Ueda, Satoko Toma, Hitomi Oki, Norihiko Tanno, Ikutaro Saji, Akira Ito, Yukihiro Ohno, Mitsutaka Nakamura.   

Abstract

Lurasidone [(3aR,4S,7R,7aS)-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl]hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned human receptors or membrane fractions prepared from animal tissue. Lurasidone was found to have potent binding affinity for dopamine D(2), 5-hydroxytryptamine 2A (5-HT(2A)), 5-HT(7), 5-HT(1A), and noradrenaline alpha(2C) receptors. Affinity for noradrenaline alpha(1), alpha(2A), and 5-HT(2C) receptors was weak, whereas affinity for histamine H(1) and muscarinic acetylcholine receptors was negligible. In vitro functional assays demonstrated that lurasidone acts as an antagonist at D(2) and 5-HT(7) receptors and as a partial agonist at the 5-HT(1A) receptor subtype. Lurasidone showed potent effects predictive of antipsychotic activity, such as inhibition of methamphetamine-induced hyperactivity and apomorphine-induced stereotyped behavior in rats, similar to other antipsychotics. Furthermore, lurasidone had only weak extrapyramidal effects in rodent models. In animal models of anxiety disorders and depression, treatment with lurasidone was associated with significant improvement. Lurasidone showed a preferential effect on the frontal cortex (versus striatum) in increasing dopamine turnover. Anti-alpha(1)-noradrenergic, anticholinergic, and central nervous system (CNS) depressant actions of lurasidone were also very weak. These results demonstrate that lurasidone possesses antipsychotic activity and antidepressant- or anxiolytic-like effects with potentially reduced liability for extrapyramidal and CNS depressant side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404009     DOI: 10.1124/jpet.110.167346

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  93 in total

Review 1.  Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.

Authors:  Michael Levine; Anne-Michelle Ruha
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Authors:  Eunice Y Yuen; Xiangning Li; Jing Wei; Masakuni Horiguchi; Herbert Y Meltzer; Zhen Yan
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

Review 3.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

Review 4.  ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496).

Authors:  Corey R Hopkins
Journal:  ACS Chem Neurosci       Date:  2011-02-16       Impact factor: 4.418

Review 5.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 6.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

7.  ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Authors:  M Kołaczkowski; P Mierzejewski; P Bieńkowski; A Wesołowska; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 8.  Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

9.  Case report of a switch to mania induced by lurasidone.

Authors:  Mark Kanzawa; Olga Hadden
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-02

10.  Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Authors:  F Calabrese; A Luoni; G Guidotti; G Racagni; F Fumagalli; M A Riva
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.